Drug reference

Ranibizumab

Monoclonal Antibody · Antineovascularisation Drug

Monoclonal AntibodyAntineovascularisation DrugATC null

CDSCO approvedSchedule H

EXCRETION

—

not curated

INTERACTIONS

—

none in our sources

PREGNANCY

Manufacturer advises avoid unless potential

FDA category + note

Mechanism

Ranibizumab is an intravitreal anti-vascular endothelial growth factor (anti-VEGF). It inhibits the activity of vascular endothelial growth factors.

Indications

Wet-active age-related macular degeneration (first-line treatment for patients with visual acuity between 6/12 and 6/96)Wet-active age-related macular degeneration (if visual acuity is less than 6/96, only if the patient’s overall visual function is likely to improve, e.g., if the affected eye is the patient’s better-seeing eye)wet macular degenerationneovascular (wet) age-related macular degenerationmacular edema following retinal vein occlusiondiabetic retinopathy (in patients with DME)

Dosing

Adult: l INDICATIONS AND DOSE Neovascular (wet) age-related macular degeneration (specialist use only) ▶ BY INTRAVITREAL INJECTION ▶ Adult: Initially 2 mg once a month for 3 months, then 2 mg every 2 months, review treatment frequency after 12 months Macular oedema secondary to retinal vein occlusion (specialist use only) ▶ BY INTRAVITREAL INJECTION ▶ Adult: Initially 2 mg once a month until maximum visu…

Contraindications

Severe, progressive loss of visual acuity despite treatment
Age-related macular degeneration develops into wet-inactive with no prospect of visual function improvement